A focused approach to winning in 2030
Oncology treatments used to promise some of the highest returns for pharmaceutical manufacturers. But spiralling R&D costs, shorter product lifecycles, fragmented patient markets and pressure on healthcare budgets are changing the industry’s status quo, threatening revenues and opening the door to new entrants.
Value-based pricing is on the rise, as cash-strapped healthcare providers attempt to cut costs. At the same time, technological advances are uncovering smaller oncology patient subsets based upon genomic and other forms of profiling.